The Italian Journal of Neurological Sciences

, Volume 19, Issue 5, pp 261–269 | Cite as

Treatment of chronic inflammatory demyelinating polyneuropathy

  • G. Comi
  • L. Roveri


The management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the main topic of this review. A few comments will also be made about treatment of the demyelinating form of paraproteinaemic demyelinating polyneuropathy (PDN) and of multifocal motor neuropathy (MMN). The review briefly describes the main characteristics of these neuropathies, and examines case series and trials which evaluated the principal therapeutic strategies for CIDP, PDN and MMN, such as intravenous immunoglobulin (IVIg) therapy, steroid treatment, plasma exchange and immunosuppressor administration. Controlled trials demonstrated that IVIg, steroid treatment and plasma exchange are effective in CIDP. For PDN the therapeutic strategies are the same as for idiopathic CIDP, but usually the clinical response is poorer. For MMN, IVIg therapy is definitely the first choice treatment.

Key words

Chronic inflammatory demyelinating polyneuropathy Immunoglobulins Corticosteroids Plasma exchange Monoclonal gammopathy Multifocal motor neuropathy 


Lo scopo principale di questa review è di esaminare le strategie terapeutiche nella neuropatia infiammatoria cronica demielineizzante (CIDP). Alcuni commenti vengono fatti anche riguardo il trattamento della forma demielinizzante della neuropatia demielinizzante paraproteinemica (PDN) e della neuropatia motoria multifocale (MMN). La review delinea le principali caratteristiche cliniche delle diverse forme di neuropatia demielinizzante ed esamina i principali studi clinici, controllati e non controllati, che hanno valutato il trattamento deila CIDP e della PDN e MMN con immunoglobuline endovena (IVIg), con la terapia steroidea, la plasmaferesi e farmaci immunosoppressori. Studi controllati hanno dimostrato che le IVIg, to steroide e la plasmaferesi sono efficaci nella CIDP. Per quanto riguarda la PDN le strategic terapeutiche sono analoghe a quelle adottate nella CIDP anche se la risposta clinica è solitamente meno evidente. Infine, nella MMN le IVIg sono sicuramente il trattamento di prima scelta.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hartung HP, Reiners K, Toyka KV, Pollard JD (1994) Giullain-Barrè syndrome and CIDP. In: Hohlfeld R (ed) Immunological neuromuscular disorders. Kluwer, Dordrecht, pp 33–104Google Scholar
  2. 2.
    Prineas JW, Mcleod JG (1976) Chronic relapsing polyneuritis. J Neurol Sci 27:427–458Google Scholar
  3. 3.
    Koski CL, Humphrey R, Shin ML (1985). Anti-peripheral myelin antibody in patients with demyelinating neuropathy: Quantitative and kinetic determination of serum antibody by complement component I fixation. Proc Natl Acad Sci USA 82:905–909Google Scholar
  4. 4.
    Van Doorn PA, Brand A, Vermeulen M (1987) Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 37:1798–1802Google Scholar
  5. 5.
    Fredman P, Vedeler CA, Nyland H et al (1991) Antibodies in antisera from patients with inflammatory demyelinating poliradiculo-neuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J Neurol 238:76–79Google Scholar
  6. 6.
    Conolly AM, Pestronk A, Trotter JL et al (1993) High titer selective serum anti β tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 43:557–562Google Scholar
  7. 7.
    Simone IL, Annunziata P, Maimone D (1993) Serum and CSF antibodies to ganglioside GM1 in Guillain-Barré syndrome and chronic inflammatory polyneuropathy. J Neurol Sci 114:49–55Google Scholar
  8. 8.
    Saida K, Sumner AJ, Saida T (1980) Antiserum mediated demyelinization: Relationship between remyelinization and functional recovery. Ann Neurol 8:12–24Google Scholar
  9. 9.
    Saida T, Saida K, Lisak RP, Brown MJ et al (1982) In vivo demyelinating activity of sera from patients with Guillain-Barrè syndrome. Ann Neurol 11:69–75Google Scholar
  10. 10.
    Heininger K, Liebert UG, Toyka KV, Haneveld FT et al (1984) Chronic inflammatory demyelinating polyradiculoneuropathy. Reduction of nerve conduction velocities in monkeys by sistemic passive transfer of immunoglobulin G. J Neurol Sci 66:1–14Google Scholar
  11. 11.
    Lassmann H, Fierz W, Neuchrist C et al (1991) Chronic relapsing esperimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines. Brain 144:429–442Google Scholar
  12. 12.
    Van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48:217–220Google Scholar
  13. 13.
    McCombe PA, Pollard JD, McLeod JG (1987) Chronic inflammatory demyelinating polyradiculoneuropathy: A clinical and electrophysiological study of 92 cases. Brain 110:1617–1630Google Scholar
  14. 14.
    Gorson KC, Allam G, Ropper AH (1997) Chronic inflammatory demyelinating polyneuropathy: Clinical feature and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48:321–328Google Scholar
  15. 15.
    Dyck PJ, Lais AC, Ohta M et al (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50:621–637Google Scholar
  16. 16.
    Barohn RJ, Kisser JT, Warmolts JR, Mendell JR (1989) Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 46:878–884Google Scholar
  17. 17.
    Hughes RAC (1990) Guillain-Barrè syndrome. Springer, Berlin Heidelberg New YorkGoogle Scholar
  18. 18.
    Cornblath DR, Chaudry V, Griffin JW (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 30:104–106Google Scholar
  19. 19.
    Dyck PJ, Prineas J, Pollard J (1993) Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low A, Poduslo JF (eds) Peripheral neuropathy, 3rd edn. WB Saunders, Philadelphia, pp 1498–1517Google Scholar
  20. 20.
    Ad Hoc Subcommittee of the American Academy of Neurology (1991) AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:617–618Google Scholar
  21. 21.
    Albers J, Kelly J (1989) Aquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve 12:435Google Scholar
  22. 22.
    Simmons Z, Albers JW, Bromberg MB, Feldman EL (1995) Long term follow-up of patients with chronic inflammatory demyelinating polyneuropathy without and with monoclonal gammopathy. Brain 118:359–368Google Scholar
  23. 23.
    Nevo Y, Pestronk A, Kornberg AJ, Connolly AM et al (1996) Childhood chronic inflammatory demyelinating neuropathies: Clinical course and long term follow-up. Neurology 47:98–102Google Scholar
  24. 24.
    Austin JH (1958) Recurrent polyneuropathies and their corticosteroid treatment. With five-year observation of a placebocontrolled case treated with corticotropin, cortisone, and prednisone. Brain 81:157–192Google Scholar
  25. 25.
    Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD et al (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11:136–141Google Scholar
  26. 26.
    DeVivo DC, Engel WK (1970) Remarkable recovery of steroid-positive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry 33:62–69Google Scholar
  27. 27.
    Levy RL, Newkirk R, Ochoa J (1979) Treating chronic relapsing Guillain-Barrè syndrome by plasma exchange (letter). Lancet 2:259–260Google Scholar
  28. 28.
    Server AC, Lefkowith J, Braine H, McKhann GM (1979) Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 6:258–261Google Scholar
  29. 29.
    Toyka KV, Augspach R, Wietholter H, Besinger UA et al (1982) Plasma exchange in chronic inflammatory polyneuropathy: Evidence suggestive of pathogenic humoral factor. Muscle Nerve 5:479–484Google Scholar
  30. 30.
    Dyck PJ, Daube J, O'Brien P et al (1986) Plasma exchange in chronic inflammatory demyelinating polyneuropathy. N Engl J Med 314:461–465Google Scholar
  31. 31.
    Hahn AF, Bolton CF, Pillay N, Chalk C et al (1996) Plasmaexchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind sham controlled cross-over study. Brain 119:1055–1066Google Scholar
  32. 32.
    Heininger K, Gibbels K, Besinger UA, Borberg H et al (1990) Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyradiculoneuropathy. In: Rock G (ed) Apheresis. Wiley-Liss, New York, pp 275–281Google Scholar
  33. 33.
    Thornton CA, Griggs RC (1994) Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease (review). Ann Neurol 35:260–268Google Scholar
  34. 34.
    Fanaroff AA, Korones SB, Wright LL et al (1994) A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 330:1007–1013Google Scholar
  35. 35.
    Schwarzt SA (1993) Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes. Clin Rev Allergy Immunol 10:1–12Google Scholar
  36. 36.
    Ronda N, Hurez V, Kazatchine MD (1993) Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 65:65–72Google Scholar
  37. 37.
    Sullivan KM, Kopecky KJ, Jocom J et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation N Engl J Med 323:705–712Google Scholar
  38. 38.
    Huang-Xuan K, Leger JM, Younes-Chennoufi B et al (1993) Traitment des neuropathies dusimmunitaires par immunoglobulines polyvalents intraveineuses. Rev Neural 149:385–392Google Scholar
  39. 39.
    Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD (1989) High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 39:422–425Google Scholar
  40. 40.
    Hodkinson SJ, Pollard JD, McLeod JG (1990) Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53:327–330Google Scholar
  41. 41.
    Nemni R, Fazio S, Fazio R, Galardi G, Previtali S, Comi G (1994) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments. J Neurol Neurosurg Psychiatry 57(Suppl):43–45Google Scholar
  42. 42.
    Vermeulen M, Van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39Google Scholar
  43. 43.
    Dyck PJ, Litchy WJ, Kratz KM et al (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845Google Scholar
  44. 44.
    Hahn AF, Bolton CF, Pillay N, Chalk C et al (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 119:1067–1077Google Scholar
  45. 45.
    Kahn SN, Riches PG, Kohn J (1980) Paraproteinemia in neurological disease: Incidence, associations, and classification of monoclonal immunoglobulins. J Clin Pathol 33:617–621Google Scholar
  46. 46.
    Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31:1480–1483Google Scholar
  47. 47.
    Krol V, Straaten MJ, Ackerstaff RG, DeMaat CE (1985) Peripheral polyneuropathy and monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 48(7):706–708Google Scholar
  48. 48.
    Osby E, Noting L, Hast R, Kjellin KG, Knutsson E, Siden A (1982) Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 51(4):531–539Google Scholar
  49. 49.
    Vrethem M, Cruz M, Huang W, Malm C, Holmgren H, Ernerudh J (1993) Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 114:193–199Google Scholar
  50. 50.
    Nobile-Orazio E, Manfredini E, Carpo M et al (1994) Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 36:416–424Google Scholar
  51. 51.
    Dalakas MC, Engel WK (1981) Polyneuropathy with monoclonal gammopathy: Studies of 11 patients. Ann Neurol 10:45–52Google Scholar
  52. 52.
    Kelly JJ, Adelman E, Berkman E, Bhan I (1988) Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 45:1355–1359Google Scholar
  53. 53.
    Yeung KB, Thomas PK, King RHM et al (1991) The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 238:383–391Google Scholar
  54. 54.
    Nobile-Orazio E, Baldini L, Barbieri S et al (1988) Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 24:93–97Google Scholar
  55. 55.
    Waterston JA, Brown MM, Ingram DA, Swash M (1992) Cyclosporin A therapy in paraprotein-associated neuropathy. Muscle Nerve 15:445–448Google Scholar
  56. 56.
    Dellagi K, Chedru F, Clauvel JP, Brouet JC (1984) Neuropathie periphédrique de la macroglobulinemie de Waldenstrom. Presse Med 13:1199–1201Google Scholar
  57. 57.
    Sherman WH, Olarte MR, McKiernan G, Sweeney K, Latov N, Hays AP (1984) Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry 47:813–819Google Scholar
  58. 58.
    Simmons Z, Bromberg MB, Feldman EL, Blaivas M (1993) Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 16:77–83Google Scholar
  59. 59.
    Dyck PJ, Low PA, Windebank AJ et al (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482–1486Google Scholar
  60. 60.
    Ellie E, Vital A, Steck A, Boiron JM, Vital C, Julien J (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological, pathological findings and response to treatment in 33 cases. J Neurol 243:34–43Google Scholar
  61. 61.
    Oksenehendler E, Chevret S, Léger JM et al (1995) Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 59:243–247Google Scholar
  62. 62.
    Cook D, Dalakas M, Galdi A, Biondi D, Porter H (1990) High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 40:212–214Google Scholar
  63. 63.
    Léger JM, Younes-Chennoufi AB, Chassande B et al (1994) Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 57(Suppl):46–49Google Scholar
  64. 64.
    Notermans NC, Lokhorst HM, Frassen H, Van Der Graaf Y, Teunissen LL, Jennekens FG, Van Den Berg LH, Wokke JH (1996) Neurology 47(5):1227–1233Google Scholar
  65. 65.
    Blume G, Pestronk A, Goodnough LT (1995) Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma-exchange and IV cyclophosphamide. Neurology 45(8):1577–1180Google Scholar
  66. 66.
    Kaji R, Hirota N, Oka N et al (1994) Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 17:108–110Google Scholar
  67. 67.
    Corse AM, Chaudry V, Crawford TO, Cornblath D, Kuncl R, Griffin J (1996) Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 39:319–325Google Scholar
  68. 68.
    Lange DJ, Trojaborg W, Latov N, Hays AP, Younger DS, Uncini A, Blake DM, Hirano M, Burns SM, Lovelace RE et al (1992) Multifocal motor neuropathy with conduction block: Is it a distinct clinical entity? Neurology 43(3 Pt 1):497–505Google Scholar
  69. 69.
    Kornberg AJ, Pestronk A (1994) The clinical and diagnostic role of anti-GMI antibody testing. Muscle Nerve 17(1):100–104Google Scholar
  70. 70.
    Feldman EL, Bromberg MB, Alberts JW, Pestronk A (1991) Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397–401Google Scholar
  71. 71.
    Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA (1990) A syndrome of asymmetric limb weakness with motor conduction block. Neurology 40:118–127Google Scholar
  72. 72.
    Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103–107Google Scholar
  73. 73.
    Pestronk A, Cornblath DR, Ilyas AA et al (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24:73–78Google Scholar
  74. 74.
    Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J (1994) Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin J Neurol Neurosurg Psychiatry 57(7):778–783Google Scholar
  75. 75.
    Van Den Berg LH, Lokhorst H, Wokke JH (1997) Neurology 48(4):1135Google Scholar
  76. 76.
    Bouche P, Moulonguet A, Younes-Chennoufi AB et al (1995) Multifocal motor neuropathy with conduction block: A study of 24 patients. J Neurol Neurosurg Psychiatry 59:38–44Google Scholar
  77. 77.
    Chaudry V, Corse AM, Cornblath DR et al (1993) Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol 33:237–242Google Scholar
  78. 78.
    Comi G, Amadio S, Galardi G, Fazio R, Nemni R (1944) Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 57(Suppl):35–37Google Scholar
  79. 79.
    Kaji R, Shibasaki H, Kimura J (1992) Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy. Neurology 42:506–509Google Scholar
  80. 80.
    Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G (1993) High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43:537–544Google Scholar
  81. 81.
    Parry GJ (1996) AAEM case report # 30: Multifocal motor neuropathy. Muscle Nerve 19:269–276Google Scholar
  82. 82.
    Azulay JP, Blin O, Pouget J et al (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 44:429–432Google Scholar
  83. 83.
    Van Den Berg LH, Kerkoff H, Oey PL et al (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252Google Scholar
  84. 84.
    Azulay JP, Rihet P, Pouget J, Cador F, Blin O, Boucraut J, Serratrice G (1997) Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 62(4):391–394Google Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • G. Comi
    • 1
  • L. Roveri
    • 1
  1. 1.Department Clinical Neurophysiology, University of MilanoScientific Institute Hospital San RaffaeleMilanoItaly

Personalised recommendations